T2D.com vs Zealthy
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
T2D.com
Best for diabetic GLP-1 accessStarting at $999/mo
Zealthy
Best for not currently recommended — listed for transparency and reader awareness onlyStarting at $286/mo
Side-by-Side Comparison
| Feature | T2D.com | Zealthy |
|---|---|---|
| Overall Score | ✓6.1/10 | 4.8/10 |
| Starting Price | $999/mo | ✓$286/mo |
| Editorial Rating | ✓3.1 ★ /5 | 2.4 ★ /5 |
| Features | ✓7 features | 3 features |
| States Available | 1 | ✓34 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 2 warnings |
Pros & Cons
T2D.com
Pros
- ✓Built specifically for type 2 diabetic and pre-diabetic patients
- ✓Integrated service — prescriber, pharmacy, and delivery handled in one flow
- ✓Offers both compounded semaglutide and compounded tirzepatide
- ✓Temperature-controlled home delivery via UPS or FedEx
- ✓Ongoing prescriber monitoring and support included
Cons
- ✗No pricing published on the public website — must register to see costs
- ✗No states list published on the site
- ✗Newer brand with limited independent reviews
- ✗Compounded only — no brand-name Ozempic, Wegovy, or Mounjaro
Zealthy
Pros
- ✓34 states served — meaningful nationwide footprint
- ✓Asynchronous model removes friction for patients comfortable without a synchronous video visit
- ✓Independent licensed prescribers retain full clinical authority
Cons
- ✗TWO FDA warning letters for false/misleading marketing of compounded GLP-1s (Feb 2026 letter 717987 verified at fda.gov; September 2025 letter from secondary sources)
- ✗Active Novo Nordisk false-advertising lawsuit: Novo Nordisk A/S et al v. Zealthy Inc., case 1:25-cv-06391 (S.D.N.Y., filed 2025-08-04), alleging trademark infringement and marketing of compounded products as 'FDA-approved alternatives'
- ✗Active DOJ/FTC enforcement: United States v. Cerebral, Inc. et al, case 1:24-cv-21376 (S.D. Fla., amended complaint adding Zealthy Inc., Gronk Inc., founder Kyle Robertson, and others), alleging ROSCA violations (failure to disclose subscription terms, no informed consent for billing, locked cancellation), and unauthorized health-data sharing for targeted advertising
- ✗Founder pattern of conduct: Kyle Robertson previously founded Cerebral, which settled with the FTC in June 2024 ($5M consumer redress + $10M civil penalty suspended to $2M) for similar deceptive practices. Robertson then founded Zealthy and is alleged to have continued the same conduct
- ✗Company recently renamed FitRX/Zealthy to Gronk Inc. — rebrand pattern is itself a concerning signal in the context of active enforcement
- ✗Continued marketing of compounded semaglutide after FDA removed it from the shortage list on 2025-02-21 (post-shortage compounding without legal authorization)
- ✗Adds a $135/month membership fee on top of medication cost — total cash price is $286-$351/month
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
Our Verdict
T2D.com edges out Zealthy with a higher overall score of 6.1/10 and is particularly strong for diabetic GLP-1 access. Zealthy remains a solid alternative, especially if you're looking for not currently recommended — listed for transparency and reader awareness only.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.